KMID : 0939920230550020523
|
|
´ëÇѾÏÇÐȸÁö 2023 Volume.55 No. 2 p.523 ~ p.530
|
|
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
|
|
Lee Dae-Won
Keam Bhum-Suk Lee Keun-Seok Ahn Jin-Hee Sohn Joo-Hyuk Ahn Jin-Seok Lee Moon-Hee Kim Jee-Hyun Lee Kyung-Eun Kim Hyo-Jung Kim Si-Young Park Yeon-Hee Ock Chan-Young Lee Kyung-Hun Han Sae-Won Kim Sung-Bae Im Young-Hyuck Chung Hyun-Cheol Oh Do-Youn Im Seock-Ah
|
|
Abstract
|
|
|
Purpose This single-arm phase II trial investigate the efficacy and safety of S-1 plus oxaliplatin (SOX) in patients with metastatic breast cancer.
Materials and Methods Patients with metastatic breast cancer previously treated with anthracyclines and taxanes were enrolled. Patients received S-1 (40-60 mg depending on patient¡¯s body surface area, twice a day, day 1-14) and oxaliplatin (130 mg/m2, day 1) in 3 weeks cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumor 1.1. Secondary endpoints included time-to-progression (TTP), duration-of-response (DoR), overall survival (OS), and adverse events.
Results A total of 87 patients were enrolled from 11 institutions in Korea. Hormone receptor was positive in 54 (62.1%) patients and six (6.9%) had human epidermal growth factor receptor 2?positive disease. Forty-eight patients (85.1%) had visceral metastasis and 74 (55.2%) had more than three sites of metastases. The ORR of SOX regimen was 38.5% (95% confidence interval [CI], 26.9 to 50.0) with a median TTP of 6.0 months (95% CI, 5.1 to 6.9). Median DoR and OS were 10.3 months (95% CI, 5.5 to 15.1) and 19.4 (95% CI, not estimated) months, respectively. Grade 3 or 4 neutropenia was reported in 28 patients (32.1%) and thrombocytopenia was observed in 23 patients (26.6%).
Conclusion This phase II study showed that SOX regimen is a reasonable option in metastatic breast cancer previously treated with anthracyclines and taxanes.
|
|
KEYWORD
|
|
Breast neoplasms, Drug therapy, S-1, Oxaliplatin, Phase II trial
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|